Preclinical imaging provides an important translational bridge between the basic science lab and the clinic. Imaging findings in human patients can drive basic science experiments, and basic science can help explain imaging findings. My work is centered on this bridge, as I am primarily interested in preclinical imaging, but in the context of unmet needs in human imaging.
I have utilized preclinical imaging to answer a variety of questions in psychiatry, oncology and nephrology, among others, since my graduate work. My early research involved examining the brain and investigating the effects of antipsychotic medications on brain composition and neurochemistry. Eventually, I transitioned to examining liver metabolism using proton, sodium, phosphorus and carbon imaging or spectroscopy with the aim of using these magnetic resonance methods to quantify liver fibrosis and stage liver disease.
In addition to pursuing my own research, I serve as the director of the In Vivo Microimaging Laboratory. I support several researchers who use imaging in their investigations of various diseases, including multiple sclerosis, neurofibromatosis, cardiac dysfunction, kidney and liver disease and genetic disorders.